PANACCIONE, ISABELLA
 Distribuzione geografica
Continente #
NA - Nord America 1.030
EU - Europa 261
AS - Asia 215
SA - Sud America 13
AF - Africa 7
OC - Oceania 1
Totale 1.527
Nazione #
US - Stati Uniti d'America 1.022
IT - Italia 90
SG - Singapore 77
CN - Cina 72
IN - India 61
SE - Svezia 52
FI - Finlandia 33
UA - Ucraina 25
DE - Germania 15
AR - Argentina 12
IE - Irlanda 12
GB - Regno Unito 11
BG - Bulgaria 10
CA - Canada 8
TG - Togo 5
FR - Francia 3
RO - Romania 3
BE - Belgio 2
ID - Indonesia 2
AU - Australia 1
BO - Bolivia 1
EG - Egitto 1
GR - Grecia 1
KR - Corea 1
LV - Lettonia 1
MY - Malesia 1
NO - Norvegia 1
PT - Portogallo 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
ZA - Sudafrica 1
Totale 1.527
Città #
Chandler 168
Fairfield 133
Ashburn 80
Singapore 58
Ann Arbor 48
Beijing 46
Houston 46
Wilmington 44
Seattle 40
Cambridge 38
Rome 36
Woodbridge 35
Princeton 32
Plano 29
Dearborn 28
Millbury 22
San Paolo di Civitate 15
Boardman 14
Boston 13
Lawrence 13
Dublin 12
Federal 12
New York 12
San Diego 12
Santa Clara 12
Bremen 11
Norwalk 10
Sofia 10
Andover 8
Jacksonville 8
Cagliari 6
Lomé 5
Toronto 5
Falls Church 4
Helsinki 4
Naples 4
Pune 4
Hefei 3
Redmond 3
San Mateo 3
Brussels 2
Buffalo 2
Indiana 2
Jakarta 2
Kunming 2
Nanjing 2
Quzhou 2
Southend 2
Stockholm 2
Acton 1
Baotou 1
Carmagnola 1
Chambly 1
Chengdu 1
Chongqing 1
Dallas 1
Des Moines 1
Fremont 1
Genova 1
Gunzenhausen 1
Lissone 1
Los Angeles 1
Melegnano 1
Milan 1
Montréal 1
Muizenberg 1
Munich 1
Nanchang 1
Oslo 1
Ottawa 1
Phoenix 1
Portici 1
Redwood City 1
Riga 1
Riyadh 1
Rödental 1
Secinaro 1
Shaoxing 1
Southwark 1
Sucre 1
Sydney 1
Thessaloniki 1
Wenzhou 1
Wuhan 1
Totale 1.139
Nome #
Neurobiological evidence for the primacy of mania hypothesis 102
Paradoxical sleep deprivation in rats causes a selective reduction in the expression of type-2 metabotropic glutamate receptors in the hippocampus 95
Increased serum Dickkopf-1 levels in drug-abusing psychotic patients 89
Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis 74
GROUP-II METABOTROPIC GLUTAMATE RECEPTOR LIGANDS AS ADJUNCTIVE DRUGS IN THE TREATMENT OF DEPRESSION: A NEW STRATEGY TO SHORTEN THE LATENCY OF ANTIDEPRESSANT MEDICATION? 72
Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. 72
Metabotropic glutamate 2/3 receptors and epigenetic modifications in psychotic disorders: a review 71
Pharmacological and psychosocial treatment of adults with gambling disorder. A meta-review 71
Low-dose acetazolamide in the treatment of premenstrual dysphoric disorder: a case series. 70
The Wnt Pathway in Mood Disorders 68
Neurodevelopment in Schizophrenia: The Role of the Wnt Pathways 67
GLI AGONISTI DEI RECETTORI METABOTROPICI DI GRUPPO II COME FARMACI IN AGGIUNTA PER LA TERAPIA DEL DISTURBO DEPRESSIVO: UNA NUOVA STRATEGIA PER RIDURRE LA LATENZA DEGLI ANTIDEPRESSIVI? 55
Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramine-induced down-regulation of beta-adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands. 53
GROUP II METABOTROPIC GLUTAMATE RECEPTOR LIGANDS INDUCE NEUROGENESIS IN CEREBELLAR GRANULAR CELL CULTURES 49
Aumento dei livelli sierici di Dickkopf-1 nei pazienti psicotici che abusano di droghe. 47
Group-II metabotropic glutamate receptor ligands as adjunctive drugs in the treatment of depressione: a new strategy to shorten the latency of antidepressant medication? 44
Constitutively active group I mGlu receptors and PKMzeta regulate synaptic transmission in developing perirhinal cortex 44
Metabotropic glutamate receptors and neuroadaptation to antidepressants: study on imipramine induced down-regulation of b–Adrenergic receptors in mice treated with mGluR2/3 receptor ligands 42
The role of memantine in the treatment of psychiatric disorders other than the dementias: A review of current preclinical and clinical evidence 42
Mechanisms of Neuroadaptation and the Regulation of Cognition 40
EFFECTS OF SERTRALINE, ESCITALOPRAM OR VENLAFAXINE TREATMENT ON SERUM BDNF LEVELS IN PATIENTS WITH ANXIETY-DEPRESSIVE DISORDERS 39
LOW CONCENTRATIONS OF MGLU2/3 METABOTROPIC GLUTAMATE RECEPTOR AGONISTS MIMIC THE ACTION OF FLUOXETINE IN PROMOTING PROLIFERATION OF CEREBELLAR GRANULE CELL NEUROPRECURSORS IN CULTURES 39
Role of PKM Zeta in synaptic plasticity in Perirhinal Cortex 37
LIVELLI SIERICI DI BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) NEI DISTURBI D’ANSIA E DELL’UMORE: EFFETTI DEGLI ANTIDEPRESSIVI 33
Metabotropic glutamate receptors and neuroadaptation to antidepressants: study on imipramine induced down-regulation of b1 –Adrenergic receptor in mice treated with mGluR2/3 ligands 31
Low concentrations of mGlu2/3 metabotropic glutamate receptor agonists mimic the action of fluoxetine in promoting proliferation of cell neuroprecursors in cultures 29
ROLE OF PKM ZETA IN LONG TERM POTENTIATION IN PERIRHINAL CORTEX 28
THE MGLU2/3 METABOTROPIC RECEPTOR AGONIST, LY379268, ENHANCES THE ANTIDEPRESSANT EFFECT OF CHLORIMIPRAMINE IN DEPRESSIVE-PRONE FLINDERS SENSITIVE LINE (FSL) RATS 18
SYNERGISM BETWEEN THE MGLU2/3 METABOTROPIC RECEPTOR AGONIST, LY379268, AND CHLORIMIPRAMINE ON ANTIDEPRESSANT EFFECT IN DEPRESSIVE-PRONE FLINDERS SENSITIVE LINE (FSL) RATS 15
Role of PKM Zeta in synaptic plasticity in perirhinal cortex 15
Bipolar disorders 15
null 15
Totale 1.581
Categoria #
all - tutte 4.802
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.802


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020251 0 0 0 0 26 46 47 38 28 28 30 8
2020/202171 6 10 1 7 2 2 2 6 7 19 4 5
2021/2022336 0 13 38 5 35 8 3 24 44 22 75 69
2022/2023361 56 74 19 73 36 34 2 27 30 4 6 0
2023/2024152 8 22 10 10 11 28 5 11 2 18 14 13
2024/2025109 18 24 20 15 32 0 0 0 0 0 0 0
Totale 1.581